These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12736598)

  • 21. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder.
    Varadharajan S; Jumadilova Z; Girase P; Ollendorf DA
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S140-9. PubMed ID: 16161387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence.
    Dmochowski RR; Sand PK; Zinner NR; Gittelman MC; Davila GW; Sanders SW;
    Urology; 2003 Aug; 62(2):237-42. PubMed ID: 12893326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapy of bladder weakness].
    Wagenlehner FM
    Dtsch Med Wochenschr; 2005 Jan; 130(3):118. PubMed ID: 15650964
    [No Abstract]   [Full Text] [Related]  

  • 24. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
    Bolge SC; McDonnell DD; Chen A; Wan GJ
    Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transdermal oxybutynin. A viewpoint by Adrian Wagg.
    Wagg A
    Drugs Aging; 2003; 20(11):865-6. PubMed ID: 12964894
    [No Abstract]   [Full Text] [Related]  

  • 26. Tolterodine for the treatment of overactive bladder.
    Salvatore S; Serati M; Bolis P
    Expert Opin Pharmacother; 2008 May; 9(7):1249-55. PubMed ID: 18422481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transdermal oxybutynin. A viewpoint by Michael Chancellor.
    Chancellor M
    Drugs Aging; 2003; 20(11):865-6. PubMed ID: 12964893
    [No Abstract]   [Full Text] [Related]  

  • 28. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.
    Ho C
    Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RE: Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence.
    Ellsworth P
    J Urol; 2003 Sep; 170(3):928; author reply 928. PubMed ID: 12913741
    [No Abstract]   [Full Text] [Related]  

  • 30. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on overactive bladder: pharmacologic approaches on the horizon.
    Rovner ES; Wein AJ
    Curr Urol Rep; 2003 Oct; 4(5):385-90. PubMed ID: 14499063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
    Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overactive bladder: improving the efficacy of anticholinergics by dose escalation.
    MacDiarmid SA
    Curr Urol Rep; 2003 Dec; 4(6):446-51. PubMed ID: 14622497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence with overactive bladder pharmacotherapy in a Medicaid population.
    Shaya FT; Blume S; Gu A; Zyczynski T; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S121-9. PubMed ID: 16161385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contemporary treatment options for overactive bladder.
    Taylor PH; Sussman DO
    JAAPA; 2005 Nov; Suppl():3-13; quiz 14-5. PubMed ID: 16315503
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
    Oki T; Kageyama A; Takagi Y; Uchida S; Yamada S
    J Urol; 2007 Feb; 177(2):766-70. PubMed ID: 17222678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do anticholinergics affect reaction time? A possible impact on the course of rehabilitation.
    Karataş GK; Günendi Z
    NeuroRehabilitation; 2010; 27(2):141-5. PubMed ID: 20871143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
    Olshansky B; Serra DB
    Clin Pharmacol Ther; 2008 Feb; 83(2):231-2; author reply 233. PubMed ID: 18043690
    [No Abstract]   [Full Text] [Related]  

  • 39. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
    Roberts RG; Garely AD; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.